Stoke Therapeutics, Inc.
NASDAQ:STOKBiotechnology
-$0.34 today
- Market cap
- $1.75B
- Beta
- 1.19
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$2.69
Volume 0.76M
Average 0.64M
STOK Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Stoke Therapeutics, Inc.NASDAQ: STOK
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses growth accelerates
Q1 FY2026 other income / expenses of $3.42M rose 17.1% year over year, ahead of the +6.7% change in trailing-twelve-month other income / expenses. Sequentially, it fell 2.6% from the prior quarter. Over 3 fiscal years it compounded at +60.9% a year.
Context
- Other income / expenses amounted to 7.4% of revenue in FY2025, down 26.5 pp from a year earlier.
- Other income / expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +17.1% holds above the trailing-twelve-month pace of +6.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 13.71M USD
- Year-over-year change
- +10.6%
- 4-year CAGR
- +169.4%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.71M | +10.6% |
| FY2024 | 2024-12-31 | 12.39M | +23.0% |
| FY2023 | 2023-12-31 | 10.07M | +206.3% |
| FY2022 | 2022-12-31 | 3.29M | +1165.0% |
| FY2021 | 2021-12-31 | 260K | — |
Other Income / Expenses vs competitors
How STOK compares with its peers on the latest reported figures
- Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +6.7% is the 3rd highest of 6, against a peer median of -1.0%.
- Other income / expenses amounts to 44.3% of revenue for STOK, versus a peer median of 18.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $292.6M USD | +517.4% | +79.2% | 187.5% | |
| LTM Sep 2026 | $21.61M USD | +11.8% | -76.4% | 2.3% | |
| LTM Mar 2026 | $14.2M USD | +6.7% | +60.9% | 44.3% | |
| LTM Mar 2026 | $13.29M USD | -1.0% | +91.1% | 18.5% | |
| LTM Mar 2026 | $9.04M USD | -25.9% | +31.2% | — | |
| LTM Mar 2026 | $1.43M USD | — | -50.1% | 155.2% | |
| LTM Mar 2026 | €840.44K EUR | -70.3% | +16.3% | 6.3% | |
| Peer median (excluding STOK) | — | -1.0% | +23.8% | 18.5% | |
Competitors are the stored peer set for STOK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 12.41M | 8.78M | 36.56M | 184.42M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 12.41M | 8.78M | 36.56M | 184.42M |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 54.17M | 77.84M | 82.23M | 89.13M | 137.92M |
| Selling, General & Admin | 31.9M | 38.92M | 41.32M | 48.79M | 67.09M |
| Operating Expenses | 86.07M | 116.76M | 123.55M | 137.93M | 205.01M |
| Depreciation & Amortization | 974K | 1.55M | 2.47M | 2.18M | 1.77M |
| EBITDA | (84.83M) | (99.52M) | (102.23M) | (86.8M) | (5.12M) |
| EBITDA Margin | — | -802.3% | -1164.4% | -237.5% | -2.8% |
| Operating Income | (86.07M) | (104.36M) | (114.77M) | (101.37M) | (20.59M) |
| Operating Margin | — | -841.2% | -1307.2% | -277.3% | -11.2% |
| Interest Income | 120K | 3.12M | 9.91M | 12.64M | 13.77M |
| Interest Expense | 0 | 0 | 0 | 0 | 9K |
| Other Income / Expenses | 260K | 3.29M | 10.07M | 12.39M | 13.71M |
| Income Before Tax | (85.81M) | (101.07M) | (104.7M) | (88.98M) | (6.89M) |
| Pre-Tax Margin | — | -814.7% | -1192.5% | -243.4% | -3.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (85.81M) | (101.07M) | (104.7M) | (88.98M) | (6.89M) |
| Net Margin | — | -814.7% | -1192.5% | -243.4% | -3.7% |
| EPS (Basic) | (2.34) | (2.60) | (2.38) | (1.65) | (0.12) |
| EPS (Diluted) | (2.34) | (2.60) | (2.38) | (1.65) | (0.12) |
| Weighted Avg Shares | 36.74M | 38.9M | 43.99M | 54.01M | 59.22M |
| Weighted Avg Shares (Diluted) | 36.74M | 38.9M | 43.99M | 54.01M | 59.22M |
Stoke Therapeutics, Inc.
NASDAQ:STOK
Intrinsic Alpha fair value
Locked
Current Price
$26.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.